ArticleBMC pediatrics2025
The timing of using IVIG for neonatal ABO hemolytic disease.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundABO hemolytic disease of the newborn (ABO HDN) is the most prevalent cause of hemolytic disease of the newborn, often leading to hyperbilirubinemia. In some cases, ABO HDN can progress to significant hyperbilirubinemia. The role of intravenous immunoglobulin (IVIG) in treating ABO HDN remains controversial. Several key questions regarding significant hyperbilirubinemia remain unanswered: What are the risk factors of ABO HDN with significant hyperbilirubinemia? Can IVIG provide benefits for ABO HDN with significant hyperbilirubinemia? Where do we place IVIG in the treatment sequence paradigm of ABO HDN? How do we best stratify ABO HDN with significant hyperbilirubinemia for IVIG therapy?
methodsWe conducted a retrospective cohort study include 948 newborns from West China Second University Hospital, divided into two groups according to the use/nonuse of IVIG. The maternal and neonatal baseline clinical data were collected from digital medical record system. The risk factors of the significant hyperbilirubinemia associated with ABO HDN were investigated using univariate and multivariate analysis. The generalized additive mixed model (GAMM) was used to analyze the nonlinear relationship of bilirubin level with different treatment over time.
resultsA total of 948 newborns fulfilled the inclusion criteria, with 143 (15.1%) in the IVIG group, and 805 (84.9%) in the non-IVIG group. (1) The multivariate analysis found that gestational age ≥ 37 weeks (OR 4.19; p = 0.019), age at admission range 24-48 h (OR 9.69; p = 0.03) and age at admission >48 h (OR 50.31; p < 0.0001) were affect significant hyperbilirubinemia in neonates. (2) The total serum bilirubin (TSB) descent speed of IVIG group (0.69µmol/L/h, 95%CI, 0.48-0.89µmol/L/h) was higher than non-IVIG group (0.21µmol/L/h, 95%CI, 0.14-0.29µmol/L/h) among the neonates with age at admission ≤ 48 h (p < 0.0001);No adverse effects related to IVIG treatment were recorded in either group.
conclusionRegular monitoring of TSB levels starting 24 h after birth is an effective strategy to prevent severe hyperbilirubinemia in ABO HDN. For southwest Chinese neonates, IVIG should not be routinely used to treat ABO HDN in those admitted > 48 h after birth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.